Natera price to free cash flow NTRA
Market value divided by free cash flow over the last twelve months, since 2025.
- Today, Nov 3, 2026
- n/m
- a sliver of free cash flow
- Last meaningful
- 367×
- Jul 2026
- Peer median
- 38.4×
Natera's price to free cash flow is not a meaningful number today: a multiple this high rests on a sliver of free cash flow.
It was last meaningful in Jul 2026, at 367×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 367× | 237× | 383× |
| 2025 | 304× | 199× | 318× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Natera's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| NTRANatera | n/m |
| IDXXIDEXX Laboratories | 41.5× |
| AAgilent Technologies | 39.1× |
| WATWaters | 117× |
| IQVIQVIA | 19.4× |
| ILMNIllumina | 38.4× |
| MTDMettler-Toledo International | 39.6× |
| LHLabcorp | 25.0× |
| DGXQuest Diagnostics | 20.0× |
| DHRDanaher | n/m |
| MEDPMedpace | 25.6× |
| Peer median | 38.4× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Natera
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.